These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 8174308

  • 1. Virilization of the voice in post-menopausal women due to the anabolic steroid nandrolone decanoate (Decadurabolin). The effects of medication for one year.
    Gerritsma EJ, Brocaar MP, Hakkesteegt MM, Birkenhäger JC.
    Clin Otolaryngol Allied Sci; 1994 Feb; 19(1):79-84. PubMed ID: 8174308
    [Abstract] [Full Text] [Related]

  • 2. A report on alterations to the speaking and singing voices of four women following hormonal therapy with virilizing agents.
    Baker J.
    J Voice; 1999 Dec; 13(4):496-507. PubMed ID: 10622516
    [Abstract] [Full Text] [Related]

  • 3. Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate.
    Need AG, Nordin BE, Chatterton BE.
    Osteoporos Int; 1993 Dec; 3 Suppl 1():218-22. PubMed ID: 8461566
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis.
    Lippi G, Guidi G, Ruzzenente O, Braga V, Adami S.
    Scand J Clin Lab Invest; 1997 Oct; 57(6):507-11. PubMed ID: 9350070
    [Abstract] [Full Text] [Related]

  • 6. Nandrolone decanoate treatment of post-menopausal osteoporosis for 2 years and effects of withdrawal.
    Hassager C, Riis BJ, Pødenphant J, Christiansen C.
    Maturitas; 1989 Dec; 11(4):305-17. PubMed ID: 2693918
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.
    Hassager C, Jensen LT, Pødenphant J, Thomsen K, Christiansen C.
    Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of nandrolone decanoate on the lipid profile of male peritoneal dialysis patients.
    Mora C, Macía ML, García J, Navarro JF.
    Perit Dial Int; 2001 Jan; 21(6):611-4. PubMed ID: 11783772
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis.
    Need AG, Horowitz M, Walker CJ, Chatterton BE, Chapman IC, Nordin BE.
    Bone; 1989 Jan; 10(1):3-6. PubMed ID: 2736154
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Hormone-induced voice disorders].
    Chernobel'skiĭ SI.
    Vestn Otorinolaringol; 1989 Jan; (4):85. PubMed ID: 2800139
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.
    Geusens P.
    Clin Rheumatol; 1995 Sep; 14 Suppl 3():32-9. PubMed ID: 8846659
    [Abstract] [Full Text] [Related]

  • 19. Anabolic steroids in corticosteroid-induced osteoporosis.
    Adami S, Rossini M.
    Wien Med Wochenschr; 1993 Sep; 143(14-15):395-7. PubMed ID: 8256456
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.